Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8585741 | 1.00 | HPGD (0.33) | HPGDCYP4F2CYP4A11HSD17B10CTSK | |
| SCHEMBL998215 | 0.87 | HPGD (0.35) | HPGDCYP4F2CYP4A11CTSKUSP2 | |
| SCHEMBL7995307 | 0.86 | MAPK1 (0.36) | — | |
| SCHEMBL7382306 | 0.83 | CYP4F2 (0.33) | HPGDCYP4F2CYP4A11CTSKUSP2 | |
| SCHEMBL4299193 | 0.80 | CYP4F2 (0.32) | CYP4F2CYP4A11CTSKUSP2SMN1; SMN2 | |
| SCHEMBL19281600 | 0.79 | CYP4F2 (0.35) | HPGDCYP4F2CYP4A11CTSKUSP2 | |
| SCHEMBL9854762 | 0.78 | CYP4F2 (0.33) | CYP4F2CYP4A11CTSK | |
| SCHEMBL18301541 | 0.77 | MMP1 (0.33) | CYP4F2CYP4A11CTSK | |
| SCHEMBL9518563 | 0.77 | CYP4F2 (0.32) | HPGDCYP4F2CYP4A11CTSKUSP2 | |
| SCHEMBL630080 | 0.76 | GRIN2B (0.38) | HPGDCYP4F2CYP4A11HSD17B10CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106349237-A | Method for preparing hydrobromic acid teneligliptin | 南通普悦生物医药有限公司 | 2017-01-25 | — | — | CN | disclosed |
| US-7989471-B2 | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-08-02 | — | — | US | disclosed |
| EP-1912995-B1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2011-07-27 | — | — | EP | disclosed |
| CN-101909446-A | Quinoxaline-containing compounds as hepatitis c virus inhibitors | ENANTA PHARM INC | 2010-12-08 | — | — | CN | disclosed |
| US-20100240698-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240698-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2B6, SRD5A1, NR5A2 | HPGD 633/4885CYP4F2 102/4885CYP4A11 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.